• Home
  • MSN Laboratories

MSN Laboratories

About MSN Laboratories

MSN Laboratories was founded in 2003 and is one of the fastest growing pharmaceutical manufacturers of APIs and finished dosages in India. We have Nine API and Five Finished dosage facilities & an integrated R&D Center located in Hyderabad.

Our state-of-the-art facilities are accredited by  USFDA, EU:GMP, WHO:Geneva, PIC/S, ANVISA, Invima and many other global approvals. With a product portfolio covering 35 major therapies including Oncology, MSN reaches out to millions of people in 65 countries across North America, Europe, Latin America, CIS, Middle East, Africa & Asia.  

Our strengths are our world-class facilities, innovation driven R&D, strong IPM,...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    India
  • On CPHI since:
    2015
Contact info
Show contact info Hide contact info
Meet us at

CPHI & PMEC China 2026

Shanghai New International Expo Center
16 Jun 2026 - 18 Jun 2026
View Exhibitor Profile

CPHI Milan 2026

Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
View Exhibitor Profile

CPHI India 2026

IICC, Yashobhoomi, Dwarka, Delhi
23 Nov 2026 - 25 Nov 2026
View Exhibitor Profile

CPHI Middle East 2026

Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia
14 Dec 2026 - 16 Dec 2026
View Exhibitor Profile

MSN Laboratories Resources (1)

  • MSN corporate overview

    Brochure MSN corporate overview

    MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 24 state-of-the-art manufacturing facilities (16 API and 8 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly.